Page 319 - SAMRC Annual Report 2024-2025

FINANCIAL INFORMATION

ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025
NOTES TO THE ANNUAL FINANCIAL STATEMENTS

(CONTINUED)

2025 2024
31 MARCH 31 MARCH
R R
18. Earmarked funds

Botha trust 151,636 151,636
Bruhns trust 1,656,823 1,544,764
Melville Douglas trust 13,325 13,325
Q&S Abdool Karim trust 3,611,535 3,334,123
FJ Kleynhans trust 111,442 111,442
5,544,761 5,155,290

The Earmarked funds are donations; bequests from deceased estates or cash received for a limited period to be
used for visiting eminent scientists; cancer research or tuberculosis research.

The Earmarked funds are held at the Reserve Bank.
The monies are ring fenced separately from the cash balances of the SAMRC refer to note 8.
The Bruhns and Q & S Abdool Karim trust funds earned interest.

19. Accumulated surplus

Accumulated surplus 473,614,819 412,948,611

The policy of the SAMRC is to maintain a reserve of R50 million to provide for any unforeseen health emergencies.
The accumulated surplus at the end of the reporting period is required to fund capital projects and other
commitments as well as the maintenance of current funding levels of research projects over the MTEF period.
The surplus will also be used to attract equivalent leverage funding from international funders.
20. Revenue

Income from contracts, grants and services rendered (exchange) 546,086,648 552,429,032
Rental income 6,023,856 6,208,292
Fair value adjustments 1,477,299 211,431
Gain on exchange differences 122,888 1,162,965
Other income 20,645,897 13,277,161
Interest received – investment 54,210,410 62,613,758
Dividends received 182,582 181,529
Government grants & subsidies 724,161,231 660,413,043
Income from contracts and grants (non-exchange) 138,597,870 134,413,603
1,491,508,681 1,430,910,814

SAMRC ANNUAL REPOR T 2025-26 317